# Effect of Lixisenatide on Postprandial Lipid Profile in Obese Type 2 Diabetic Patients

> **NCT02274740** · PHASE2 · TERMINATED · sponsor: **Sanofi** · enrollment: 2 (actual)

## Conditions studied

- Type II Diabetes Mellitus

## Interventions

- **DRUG:** LIXISENATIDE AVE0010
- **DRUG:** metformin

## Key facts

- **NCT ID:** NCT02274740
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-04
- **Primary completion:** 2015-08
- **Final completion:** 2015-08
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** Sponsor decision not related to safety reasons
- **Last updated:** 2017-01-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02274740

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02274740, "Effect of Lixisenatide on Postprandial Lipid Profile in Obese Type 2 Diabetic Patients". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02274740. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*